350 Episoade

  1. 308: An ASCO preview & another Duchenne trial failure

    Publicat: 30.05.2024
  2. 307: More tumult at BIO & coercive care for sickle cell patients

    Publicat: 23.05.2024
  3. 306: Live! From the STAT Breakthrough Summit West

    Publicat: 16.05.2024
  4. 305: Everything you need to know about H5N1 bird flu

    Publicat: 09.05.2024
  5. 304: Controversial brain tissue research, obesity drug sales and Novartis’ M&A drama

    Publicat: 02.05.2024
  6. 303: A new obesity startup, an acquisition gone wrong, & the future of Teledoc

    Publicat: 18.04.2024
  7. 302: Vertex's big deal, biotech's red numbers, & an industry history lesson

    Publicat: 11.04.2024
  8. 301: Biotech mega-rounds, a cancer vaccine setback & CEOs keep their promise

    Publicat: 04.04.2024
  9. 300: What the mifepristone case means, GLP-1 skepticism, & Chinese biotech

    Publicat: 28.03.2024
  10. 299: Live! From the STAT Breakthrough Summit East

    Publicat: 21.03.2024
  11. 298: A dilemma in ALS, the first MASH drug, & why gene therapy is hard

    Publicat: 14.03.2024
  12. 297: VC turmoil, GLP-1 competition, & the war on recovery

    Publicat: 07.03.2024
  13. 296: Legal insider trading, booming biotech stocks, & the next GLP-1

    Publicat: 29.02.2024
  14. 295: Humira’s legacy, CEO symbolism, and genomic surgery

    Publicat: 22.02.2024
  15. 294: Pharma goes to Washington, Alnylam's future, & Gilead's dealmaking

    Publicat: 15.02.2024
  16. 293: AI in medicine, detangling hype, and Icelandic DNA

    Publicat: 08.02.2024
  17. 292: Vertex's polarizing data, Aduhelm's adieu, & an FDA icon

    Publicat: 01.02.2024
  18. 291: The plight of the VC, Gilead's latest setback, & more M&A

    Publicat: 25.01.2024
  19. 290: Biotech layoffs, slumping stocks, and a 2024 preview

    Publicat: 18.01.2024
  20. 289: Live! From #JPM24

    Publicat: 11.01.2024

3 / 18

STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.

Visit the podcast's native language site